

PATENT COOPERATION TREATY

TRANSLATION INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 05814WO FOR FURTHE			ACTION	See Form PCT/IPEA/416			
			ate (day/month/year)	Priority date (day/month/year)			
PCT/JP2005/006429 25.03.200				25.03.2004			
·				23.03.2001			
International Patent Classification (IPC) or national classification and IPC G01N33/50, C12Q1/26							
Applicant FUENCE CO., LTD.							
	This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.						
2. This	REPORT consists of	a total of 6	sheets, including	ng this cover sheet.			
3. This	report is also accompa	anied by ANNEXES, comprising	:				
a. [(sent to the app	dicant and to the International B	ureau) a total of	sheets, as follows:			
u. <u>L</u>	sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative						
	Instructions). sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental						
ь. [Box. b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))						
				, containing a sequence listing and/or tables			
	related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
4. This	report contains indica	tions relating to the following ite	ms:				
\boxtimes	Box No. I E	Basis of the report					
	Box No. II P	riority					
	Box No. III N	ion-establishment of opinion with	h regard to novelty, inven	tive step and industrial applicability			
	Box No. IV L	ack of unity of invention					
\boxtimes	DON 110.	teasoned statement under Article itations and explanations support		elty, inventive step or industrial applicability;			
	Box No. VI	Certain documents cited					
	Box No. VII C	Certain defects in the internationa	l application				
\square	Box No. VIII Certain observations on the international application						
Date of submis	sion of the demand		Date of completion of the	his report			
				-			
Name and mailing address of the IPEA/JP			Authorized officer				
Faccinile Vo			Telephone No				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2005/006429

Box	No. I	Basis of the report	
1.		h regard to the language, this report is based on the internal cated under this item.	tional application in the language in which it was filed, unless otherwise
		This report is based on translations from the original lang which is the language of a translation furnished for the put international search (Rule 12.3 and 23.1(b))	uage into the following language, arposes of:
		publication of the international application (Rule 12	2.4)
		international preliminary examination (Rule 55.2 an	
2.	rece		is report is based on (replacement sheets which have been furnished to the are referred to in this report as "originally filed" and are not annexed to
		pages	as originally filed/furnished
		pages*	received by this Authority on
		pages*	received by this Authority on
		the claims:	
		nos.	as originally filed/furnished
		nos.*	as amended (together with any statement) under Article 19
		nos.*	received by this Authority on
			received by this Authority on
		the drawings:	
		sheets	as originally filed/furnished
		sheets*	received by this Authority on
		sheets*	
	П	a sequence listing and/or any related table(s) - see Supple	
3.	$\overline{\Box}$	The amendments have resulted in the cancellation of:	
<i>J</i> .	_	the description, pages	
			-
		the drawings, sheets/figs the sequence listing (specify):	
		any table(s) related to sequence listing (specify):	
4.			andments annexed to this report and listed below had not been made, since
	ш	they have been considered to go beyond the disclosure as	filed, as indicated in the Supplemental Box (Rule 70.2(c)).
		the description, pages	
		the claims, nos.	
		the drawings, sheets/figs	
		the sequence listing (specify):	
		any table(s) related to sequence listing (specify):	
*	lf ite	em 4 applies, some or all of those sheets may be marked "si	uperseded."

International application No.
PCT/JP2005/006429

Bo	x No. V			rticle 35(2) with regard to novelty, inventive step or industrial applicability; pporting such statement	
1.	Statement				
	Novelty	(N)	Claims	1-8	YES
			Claims		NO
	Inventive step (IS)	e step (IS)	Claims	· .	YES
			Claims	1-8	NO
	Industria	l applicability (IA)	Claims	1-8	YES
			Claims		NO

2. Citations and explanations (Rule 70.7)

Document 1: JP 2002-520360 A (The Picower Institute for Medical Research), 09 July 2002, refer to paragraphs [0002] to [0003], [0013] to [0014] and [0032] to [0040], and the examples, etc. & US 6391899 A

Document 2: JP 2002-281999 A (Kazuhiro IGARASHI), 02 October 2002, test 2

Document 3: JP 2002-181820 A (Ikagaku Co., Ltd.), 26 June 2002, claims and paragraph [0002]

Claims 1, 2, 4 and 5

Document 1 indicates that polyamine oxidases and polyamines such as spermine or spermidine are associated with cerebrovascular accidents and cerebral ischemia.

Thus, it would have been easy for a person skilled in the art to conceive of using measured polyamine levels and/or measured polyamine oxidase levels in order to screen patients and diagnose cerebrovascular accidents or the like.

Consequently, claims 1, 2, 4 and 5 do not involve an inventive step.

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Claims 3 and 6

Document 2 indicates that polyamine oxidases produce 3-aminopropanal from polyamines, whereafter the 3-aminopropanal immediately forms acrolein.

Meanwhile, document 1 indicates that the polyamine oxidases generate 3-aminopropanal from the polyamines, and thus it is thought that acrolein will also be present when polyamine oxidases and polyamines are present.

As a result, it would have been easy for a person skilled in the art to conceive of using acrolein as an indicator for detecting cerebrovascular accidents and/or cerebral ischemia.

Consequently, claims 3 and 6 do not involve an inventive step. $\ensuremath{\text{\text{c}}}$

Furthermore, document 3 indicates that it is possible to detect arteriosclerosis by detecting for anti-acrolein antibodies, and also indicates that arteriosclerosis is a primary cause of cerebral infarctions and the like.

As a result, it would have been easy for a person skilled in the art to conceive of detecting cerebral infarctions by detecting for acrolein.

Consequently, claims 3 and 6 do not involve an inventive step.

Claims 7 and 8

In addition, document 1 indicates that the polyamine oxidase activity is elevated for a number of hours subsequent to the onset of ischemia, and also indicates that it is possible to confirm whether the activity of the polyamine oxidase is elevated before it is possible to confirm the presence of a characteristic

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2005/006429

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
patter	rn within a diagnostic image of the head.
·	Consequently, claims 7 and 8 do not involve an
invent	tive step.
	·

International application No. PCT/JP2005/006429

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

- 1. The inventions set forth in the present application use the polyamine level or the aldehyde level as an indicator for detecting cerebrovascular accidents or the like. However, the description only describes the relationship between cerebrovascular accidents and FDP-Lys, and thus there is not considered to be sufficient support for the inventions set forth in the present application (furthermore, there is insufficient support for the claim that is possible to determine the acrolein level by measuring the FDP-Lys level).
- 2. Claims 7 and 8 of the present application indicate that statistically significant changes in the activity and/or the level of the polyamine oxidases will occur before it becomes possible to detect anything in a diagnostic image of the head. However, the description only presents one example in which this assertion holds true, and thus there is not considered to be sufficient support for the inventions set forth in claims 7 and 8.